Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 132, Issue 7, Pages 1711-1717
Publisher
Wiley
Online
2012-08-28
DOI
10.1002/ijc.27800
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Perivascular Epithelioid Cell Tumors (PEComas) Harboring TFE3 Gene Rearrangements Lack the TSC2 Alterations Characteristic of Conventional PEComas
- (2012) Izabela Malinowska et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial
- (2011) D. M. Davies et al. CLINICAL CANCER RESEARCH
- Validation of a TFE3 Break-apart FISH Assay for Xp11.2 Translocation Renal Cell Carcinomas
- (2011) Juan-Miguel Mosquera et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
- (2011) Francis X. McCormack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiomyolipoma Have Common Mutations in TSC2 but No Other Common Genetic Events
- (2011) Wei Qin et al. PLoS One
- Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease
- (2011) Sandra L. Dabora et al. PLoS One
- A Distinctive Subset of PEComas Harbors TFE3 Gene Fusions
- (2010) Pedram Argani et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Updating progress in sarcoma therapy with mTOR inhibitors
- (2010) J.- Y. Blay ANNALS OF ONCOLOGY
- Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa
- (2010) A. Italiano et al. ANNALS OF ONCOLOGY
- Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
- (2010) R. Quek et al. CLINICAL CANCER RESEARCH
- Resistance to Mammalian Target of Rapamycin Inhibitor Therapy in Perivascular Epithelioid Cell Tumors
- (2010) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors
- (2010) Andrew J. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- mTOR: from growth signal integration to cancer, diabetes and ageing
- (2010) Roberto Zoncu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Perivascular epithelioid cell neoplasms: pathology and pathogenesis
- (2009) Andrew L. Folpe et al. HUMAN PATHOLOGY
- Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis
- (2009) Kristen Pollizzi et al. Molecular Cancer
- The Pharmacology of mTOR Inhibition
- (2009) D. A. Guertin et al. Science Signaling
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
- (2008) John J. Bissler et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started